Cargando…

An Overview of siRNA Delivery Strategies for Urological Cancers

The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) see...

Descripción completa

Detalles Bibliográficos
Autores principales: Halib, Nadia, Pavan, Nicola, Trombetta, Carlo, Dapas, Barbara, Farra, Rossella, Scaggiante, Bruna, Grassi, Mario, Grassi, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030829/
https://www.ncbi.nlm.nih.gov/pubmed/35456552
http://dx.doi.org/10.3390/pharmaceutics14040718
_version_ 1784692238636285952
author Halib, Nadia
Pavan, Nicola
Trombetta, Carlo
Dapas, Barbara
Farra, Rossella
Scaggiante, Bruna
Grassi, Mario
Grassi, Gabriele
author_facet Halib, Nadia
Pavan, Nicola
Trombetta, Carlo
Dapas, Barbara
Farra, Rossella
Scaggiante, Bruna
Grassi, Mario
Grassi, Gabriele
author_sort Halib, Nadia
collection PubMed
description The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers.
format Online
Article
Text
id pubmed-9030829
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90308292022-04-23 An Overview of siRNA Delivery Strategies for Urological Cancers Halib, Nadia Pavan, Nicola Trombetta, Carlo Dapas, Barbara Farra, Rossella Scaggiante, Bruna Grassi, Mario Grassi, Gabriele Pharmaceutics Review The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers. MDPI 2022-03-27 /pmc/articles/PMC9030829/ /pubmed/35456552 http://dx.doi.org/10.3390/pharmaceutics14040718 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Halib, Nadia
Pavan, Nicola
Trombetta, Carlo
Dapas, Barbara
Farra, Rossella
Scaggiante, Bruna
Grassi, Mario
Grassi, Gabriele
An Overview of siRNA Delivery Strategies for Urological Cancers
title An Overview of siRNA Delivery Strategies for Urological Cancers
title_full An Overview of siRNA Delivery Strategies for Urological Cancers
title_fullStr An Overview of siRNA Delivery Strategies for Urological Cancers
title_full_unstemmed An Overview of siRNA Delivery Strategies for Urological Cancers
title_short An Overview of siRNA Delivery Strategies for Urological Cancers
title_sort overview of sirna delivery strategies for urological cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030829/
https://www.ncbi.nlm.nih.gov/pubmed/35456552
http://dx.doi.org/10.3390/pharmaceutics14040718
work_keys_str_mv AT halibnadia anoverviewofsirnadeliverystrategiesforurologicalcancers
AT pavannicola anoverviewofsirnadeliverystrategiesforurologicalcancers
AT trombettacarlo anoverviewofsirnadeliverystrategiesforurologicalcancers
AT dapasbarbara anoverviewofsirnadeliverystrategiesforurologicalcancers
AT farrarossella anoverviewofsirnadeliverystrategiesforurologicalcancers
AT scaggiantebruna anoverviewofsirnadeliverystrategiesforurologicalcancers
AT grassimario anoverviewofsirnadeliverystrategiesforurologicalcancers
AT grassigabriele anoverviewofsirnadeliverystrategiesforurologicalcancers
AT halibnadia overviewofsirnadeliverystrategiesforurologicalcancers
AT pavannicola overviewofsirnadeliverystrategiesforurologicalcancers
AT trombettacarlo overviewofsirnadeliverystrategiesforurologicalcancers
AT dapasbarbara overviewofsirnadeliverystrategiesforurologicalcancers
AT farrarossella overviewofsirnadeliverystrategiesforurologicalcancers
AT scaggiantebruna overviewofsirnadeliverystrategiesforurologicalcancers
AT grassimario overviewofsirnadeliverystrategiesforurologicalcancers
AT grassigabriele overviewofsirnadeliverystrategiesforurologicalcancers